BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Irinotecan: trial readouts and FDA decisions
5 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 8 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, AbbVie, Beijing Konruns Pharmaceutical Co., Ltd., CStone Pharmaceuticals, Akeso, LaNova Medicines Zhejiang Co., Ltd., Merck Sharp & Dohme LLC, Taiho Oncology, Inc., Beijing Konruns Pharmaceutical Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., LaNova Medicines Zhejiang Co., Ltd., Taiho Oncology, Inc., Idience Co., Ltd., Revolution Medicines, Inc., Actuate Therapeutics Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | AbbVie ABBV | NCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Met | Unresectable Metastatic Colorectal Cancer | active not recruiting | 280 |
| 2026-12-30 est. | P3 | Beijing Konruns Pharmaceutical Co., Ltd. | NCT06194734 A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | Esophageal Squamous Cell Carcinoma | recruiting | 490 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-01-13 est. | P3 | Akeso | NCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | Colorectal Adenocarcinoma | recruiting | 560 |
| 2026-12-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | active not recruiting | 464 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-17 est. | P2 | AstraZeneca AZN | NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarci | recruiting | 226 |
| 2026-11-10 est. | P3 | LaNova Medicines Zhejiang Co., Ltd. | NCT06351020 LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | active not recruiting | 387 |
| 2026-10-19 | P3 | Merck Sharp & Dohme LLC MRK | NCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Gastroesophageal Cancer | active not recruiting | 473 |
| 2026-10-01 est. | P2 | Taiho Oncology, Inc. | NCT05945823 Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Esophageal Ade | active not recruiting | 53 |
| 2026-07-31 est. | P1/P2 | Idience Co., Ltd. | NCT04725994 Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer | Gastric Cancer | active not recruiting | 87 |
| 2026-06 est. | P3 | Revolution Medicines, Inc. RVMD | NCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma | active not recruiting | 500 |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
| 2026-05-31 | P3 | AstraZeneca AZN | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Ad | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 594 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.